Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Johnson and Johnson
Baxter
Moodys
Boehringer Ingelheim

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,641,843

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,641,843 protect, and when does it expire?

Patent 6,641,843 protects ZIAGEN and is included in one NDA.

Protection for ZIAGEN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in thirty-eight countries.

Summary for Patent: 6,641,843
Title: Pharmaceutical compositions
Abstract:The present invention relates to pharmaceutical compostions of (1S,4R)-cis-4-[2-amino-6-cyclopropylamino}-9H-purin-9-yl]-2-cyclopentene-1 -methanol (1592U89).
Inventor(s): Brooks; Nikki Thoennes (Glen Allen, VA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/601,671
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,641,843
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Formulation;

Drugs Protected by US Patent 6,641,843

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Viiv Hlthcare ZIAGEN abacavir sulfate SOLUTION;ORAL 020978-001 Dec 17, 1998 AA RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,641,843

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9802472Feb 06, 1998
PCT Information
PCT FiledFebruary 04, 1999PCT Application Number:PCT/EP99/00663
PCT Publication Date:August 12, 1999PCT Publication Number: WO99/39691

International Family Members for US Patent 6,641,843

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1212   Start Trial
Argentina 017455   Start Trial
Austria 237309   Start Trial
Australia 2722199   Start Trial
Australia 754255   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKesson
AstraZeneca
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.